Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články
PubMed
29333622
PubMed Central
PMC5867113
DOI
10.1111/bcp.13499
Knihovny.cz E-zdroje
- Klíčová slova
- carbonic anhydrase inhibitor, dorzolamide, drug-induced anaemia, drug-induced metabolic acidosis,
- MeSH
- acidóza chemicky indukované MeSH
- anemie chemicky indukované MeSH
- aplikace oční MeSH
- glaukom farmakoterapie MeSH
- inhibitory karboanhydras aplikace a dávkování škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- renální insuficience komplikace MeSH
- sulfonamidy aplikace a dávkování škodlivé účinky MeSH
- thiofeny aplikace a dávkování škodlivé účinky MeSH
- únava chemicky indukované MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- dorzolamide MeSH Prohlížeč
- inhibitory karboanhydras MeSH
- sulfonamidy MeSH
- thiofeny MeSH
Topical carbonic anhydrase inhibitors (CAI), used for treatment of glaucoma, are generally regarded as safe and unconnected with systemic side effects. We report an unusual case of fatigue, metabolic acidosis, and normocytic anaemia associated with ocular administration of the CAI, dorzolamide, in a patient with impaired renal function. In chronic kidney disease, where CAI elimination may be decreased, and patients prone to develop metabolic acidosis, systemic absorption of ocular administered CAI could lead to rare, but potentially serious adverse reaction, that are a consequence of inhibition of extraocular carbonic anhydrase isoenzymes.
2nd Department of Internal Medicine 3rd Faculty of Medicine Charles University Prague Czech Republic
Zobrazit více v PubMed
Swenson ER. Safety of carbonic anhydrase inhibitors. Expert Opin Drug Saf 2014; 13: 459–472. PubMed
Balfour JA, Wilde MI. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997; 10: 384–403. PubMed
Martens‐Lobenhoffer J, Banditt P. Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet 2002; 41: 197–205. PubMed
DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000; 44 (Suppl 2): S119–S129. PubMed
March WF, Ochsner KI. The long‐term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open‐angle glaucoma or ocular hypertension. The Brinzolamide Long‐Term Therapy Study Group. Am J Ophthalmol 2000; 129: 136–143. PubMed
Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967; 47: 595–781. PubMed
Kitterer D, Schwab M, Alscher MD, Braun N, Latus J. Drug‐induced acid‐base disorders. Pediatr Nephrol (Berlin, Germany) 2015; 30: 1407–1423. PubMed
Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol 2016; 12: 423–431. PubMed
Morris S, Geh V, Nischal KK, Sahi S, Ahmed MAS. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol 2003; 87: 1052–1053. PubMed PMC
Capino AC, Dannaway DC, Miller JL. Metabolic acidosis with ophthalmic dorzolamide in a neonate. J Pediatr Pharmacol Ther 2016; 21: 256–259. PubMed PMC
Menon GJ, Vernon SA. Topical brinzolamide and metabolic acidosis. Br J Ophthalmol 2006; 90: 247–248. PubMed PMC
Carlsen J, Durcan J, Zabriskie N, Swartz M, Crandall A. Nephrolithiasis with dorzolamide. Arch Ophthalmol (Chicago, Ill 1960) 1999; 117: 1087–1088. PubMed
Mogk LG, Cyrlin MN. Blood dyscrasias and carbonic anhydrase inhibitors. Ophthalmology 1988; 95: 768–771. PubMed
Fraunfelder FT, Bagby GC. Monitoring patients taking oral carbonic anhydrase inhibitors. Am J Ophthalmol 2000; 130: 221–223. PubMed
Fraunfelder FT, Meyer SM, Bagby GC Jr, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol 1985; 100: 79–81. PubMed
Keisu M, Wiholm BE, Ost A, Mortimer O. Acetazolamide‐associated aplastic anaemia. J Intern Med 1990; 228: 627–632. PubMed
Kodjikian L, Durand B, Burillon C, Rouberol F, Grange J, Renaudier P. Acetazolamide‐induced thrombocytopenia. Arch Ophthalmol (Chicago, Ill 1960) 2004; 122: 1543–1544. PubMed
Martin XD, Danese M. Dorzolamide‐induced immune thrombocytopenia: a case report and literature review. J Glaucoma 2001; 10: 133–135. PubMed
Santos VM, Castro RA, Lima CC, Moraes MB, Sugai TAM. Skin eruption and thrombocytopaenia in a woman with glaucoma: a case report. West Indian Med J 2010; 59: 102–105. PubMed
Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ (Clin Res ed) 2006; 333: 1267–1269. PubMed PMC
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, et al (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. https://doi.org/10.1093/nar/gkx1121. PubMed DOI PMC
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, et al The Concise Guide to PHARMACOLOGY 2017/18: G protein‐coupled receptors. Br J Pharmacol 2017; 174: S17–S129. PubMed PMC
Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E, et al The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol 2017; 174: S272–S359. PubMed PMC
